ArticleFrontiers in neuroscience2025
A novel fluorescent probe, triphenylamine rhodamine-3-acetic acid (mRA) for the detection of Amyloid-β aggregates in Alzheimer's disease.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-Assembled EGCG@Zn Fluorescent Nanocomplexes for Sensitive Detection of Amyloid-βJournal of fluorescence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid-β (Aβ) is implicated in the pathophysiology of Alzheimer's disease (AD) and plays a significant role in neuronal degeneration. Aβ in solution is essential during the initial stages of developing lead compounds that influence Aβ fibrillation. The tendency of the Aβ peptide to misfold in solution is correlated with the etiology of AD. Therefore, the early detection of Aβ serves as a critical foundation for diagnostic testing and routine clinical assessment of AD. Herein, an aggregation-induced fluorescence probe, triphenylamine rhodamine-3-acetic acid (mRA), was used to detect Aβ aggregates. The fluorescence results showed a strong interaction between the fluorescence probe mRA and Aβ aggregates. mRA specifically binds with high affinity to Aβ aggregates, and the limit of detection (LOD) of Aβ aggregates was 0.12 μg/mL. Molecular docking studies showed that the mRA has significant binding affinity toward the Aβ peptide at the N/C-terminal region, with a binding energy of -6.5 kcal/mol. Furthermore, CD studies confirmed that the mRA binds to Aβ aggregates, and its binding induces significant structural alteration of the Aβ aggregates. Thermodynamic properties revealed that the binding of Aβ aggregates to mRA is a spontaneous process, driven by enthalpy and favored by entropy, which helps further our understanding of the interaction between mRA and Aβ aggregates at the molecular level. The negative ΔH suggests that hydrogen bonding is a dominant force for the mRA interaction with Aβ aggregates. This study provides a rationale for using mRA as a biosensor for the detection of Aβ aggregates in biological fluids, offering a potential tool for the early diagnosis and monitoring of amyloid progression in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.